Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Seit 30 Jahren erscheint der Arzneiverordnungs-Report mit Daten, Analysen und Kommentaren zur Verordnung von Arzneimitteln. Erklärte Ziele des Buches sind seitdem die Transparenz des Arzneimittelmarkts, die Bewertung von Arzneimitteln und die evidenzbasierte Arzneitherapie. Jährlich werden die Rezepte für die Patienten der gesetzlichen Krankenversicherung (GKV) analysiert. 2013 haben 202.965 Vertragsärzte 819 Mio. Arzneiverordnungen im Wert von 32,1 Mrd. € (+3,2 %) ausgestellt. Seit 3 Jahren ist die Nutzenbewertung gemäß Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) etabliert. Damit wurde erreicht, dass neue Arzneimittel in Deutschland nicht mehr teurer sind als in den europäischen Nachbarländern.  Die Nutzenbewertung von Arzneimitteln des Bestandsmarkts wurde im April dieses Jahres gestoppt, obwohl die Ärzteschaft die Fortführung gefordert hatte. So werden die Patienten weiterhin mit überhöhten Arzneimittelkosten belastet, obwohl die GKV schon 3,0 Mrd. € zusätzliche Rabatte von der Pharmaindustrie erhält. Weitere Kosten könnten bei Analogpräparaten (2,4 Mrd. €), Patentarzneimitteln des Bestandsmarkts (2,0 Mrd. €) und umstrittenen Arzneimitteln (0,5 Mrd. €) gespart werden.

Pharmacy management. --- Pharmacy. --- Health economics. --- Public health. --- Internal medicine. --- Pharmacoeconomics and Health Outcomes. --- Health Economics. --- Public Health. --- Internal Medicine.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

‘If you’re not involving patients, you're not doing HTA!’ - Dr. Brian O’Rourke, President and CEO of CADTH, Chair of INAHTA This is the first book to offer a comprehensive guide to involving patients in health technology assessment (HTA). Defining patient involvement as patient participation in the HTA process and research into patient aspects, this book includes detailed explanations of approaches to participation and research, as well as case studies. Patient Involvement in HTA enables researchers, postgraduate students, HTA professionals and experts in the HTA community to study these complementary ways of taking account of patients’ knowledge, experiences, needs and preferences. Part I includes chapters discussing the ethical rationale, terminology, patient-based evidence, participation and patient input. Part II sets out methodology including: Qualitative Evidence Synthesis, Discrete Choice Experiments, Analytical Hierarchy Processes, Ethnographic Fieldwork, Deliberative Methods, Social Media Analysis, Patient-Reported Outcome Measures, patients as collaborative research partners and evaluation. Part III contains 15 case studies setting out current activities by HTA bodies on five continents, health technology developers and patient organisations. Each part includes discussion chapters from leading experts in patient involvement. A final chapter reflects on the need to clearly define the goals for patient involvement within the context of the HTA to identify the optimal approach. With cohesive contributions from more than 80 authors from a variety of disciplines around the globe, it is hoped this book will serve as a catalyst for collaboration to further develop patient involvement to improve HTA.

Medicine. --- Public policy. --- Pharmacy management. --- Medicine & Public Health. --- Pharmacoeconomics and Health Outcomes. --- Public Policy. --- Medical technology --- Evaluation. --- Health care technology --- Health technology --- Technology --- Pharmacy --- Pharmacy administration --- Drugstores --- Health services administration --- Administration --- Management

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Representing the first book on the topic, this work offers the reader an introduction to the Japanese systems for health technology assessment (HTA) officially introduced by the Ministry of Health, Labour and Welfare (MHLW) in 2016. Policy and guidelines are discussed, with the relevant methods and conditions of cost-effectiveness analysis explained alongside. Numerous instructive examples and exercises, ranging from basic to advanced, impart valuable knowledge and insight on the quantitative methods for economic evaluation, which will appeal to both beginners and experts. This guidebook is authored by Japan’s foremost expert in HTA and pharmacoeconomics, with a view to strengthening the reader’s expertise in value-based healthcare and decision-making. The methods presented are essential to informing regulatory, local and patient decisions; as such, the book is equally recommended to industry and government, as well as academia, and anyone with an interest in Japanese HTA.

Medical economics. --- Economics, Medical --- Health --- Health economics --- Hygiene --- Medical care --- Medicine --- Economic aspects --- Health economics. --- Pharmacy management. --- Health Economics. --- Pharmacoeconomics and Health Outcomes. --- Pharmacy --- Pharmacy administration --- Drugstores --- Health services administration --- Administration --- Management

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book explains the Food and Drug Administration (FDA) as an institution and provides understanding of its nomenclature, societal role, policies, goals and challenges. While many readers will have some knowledge of the FDA, few have an appreciation of the many specific areas of FDA authority. For example, how many realize that the US is one of only two countries which allow direct-to-consumer drug advertising, which is regulated by FDA?  Or that FDA itself advertises to try to prevent young people from smoking cigarettes, and that all proprietary drug names must be approved by FDA?  How many doctors or other readers are familiar with the formal definition distinguishing drugs from devices and the importance this has for development costs and for our knowledge about the ultimate products?   How many know how much nutritional supplements are regulated by FDA? The FDA for Doctors is not for those looking for detailed instruction on dealing with the FDA or its operations.  Rather, it is written by a doctor with doctors in mind, with the hope that the information in this book will make physicians, and other readers, more thoughtful and insightful, especially with regards to therapeutics and the many broad societal issues underlying FDA’s activities. With over 40 years of experience as a clinical investigator in many  trials done for FDA registration, the author has been a member of and chaired an FDA advisory committee, and has been a consultant to several divisions of the FDA.  He has also had the opportunity to serve on the U.S. Senate Labor Committee, helping with its FDA oversight activities.  In addition to a long academic medical career the author has been a consultant to and a full time employee of drug and device companies.    .

Pharmaceutical policy --- United States. --- FDA --- F.D.A. --- U.S. Food & Drug Administration --- Medicine. --- Practice of medicine. --- Medicine/Public Health, general. --- Health Administration. --- Pharmacoeconomics and Health Outcomes. --- Medical practice --- Practice of medicine --- Physician practice acquisitions --- Clinical sciences --- Medical profession --- Human biology --- Life sciences --- Medical sciences --- Pathology --- Physicians --- Health Workforce --- Health administration. --- Pharmacy management. --- Pharmacy --- Pharmacy administration --- Drugstores --- Health services administration --- Administration --- Management

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This comprehensive guide covers prescribing controlled substances for patients with acute or chronic pain and provides a balanced discussion on appropriate treatment, addiction, safety and complications. Chapters feature evidence-based strategies and clinical modalities that address diagnostic challenges, treatment guidance, alternatives to opioid management and the significant legal risks within the current regulatory environment. Authored by leaders in pain medicine, physicians and appropriate health care professionals will find Controlled Substance Management in Chronic Pain to be an indispensable resource. .

Medicine. --- Pain medicine. --- Primary care (Medicine). --- Pharmacotherapy. --- Pharmacy management. --- Medicine & Public Health. --- Pain Medicine. --- Pharmacoeconomics and Health Outcomes. --- Primary Care Medicine. --- Chronic pain --- Chemotherapy. --- Persistent pain --- Diseases --- Pain --- Emergency medicine. --- Medicine, Emergency --- Medicine --- Critical care medicine --- Disaster medicine --- Medical emergencies --- Algiatry --- Primary medical care --- Medical care --- Pharmacy --- Pharmacy administration --- Drugstores --- Health services administration --- Drug therapy --- Pharmacotherapy --- Therapeutics --- Drugs --- Pharmacology --- Administration --- Management